Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …

Background Most patients with ovarian cancer will relapse after receiving frontline platinum-
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …

Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

Background Although most patients with epithelial ovarian cancer respond to frontline
platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 …

Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Importance Platinum-based chemotherapy has been the standard of care for ovarian cancer
for the past 3 decades. Although most patients respond to platinum-based treatment …

Ovarian cancer (OC) is one of the most common gynecologic tumors worldwide and one
with the highest mortality. Cisplatin (DDP) is the first platinum-based complex approved by …

In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …

Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …